Legend Biotech Corp. (LEGN) intrinsic value & 10-year financials
Legend Biotech Corp. (LEGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 54.4% a year to $1.0B, with an average return on invested capital of -113.6%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $1.0B
- Revenue growth (9-yr CAGR)
- 54.4%
- ROIC (10-yr avg)
- -113.6%
- Free cash flow (FY2025)
- -$128.8M
LEGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.0B | -$296.8M | -$0.81 | -$128.8M | -13.3% | -19.2% |
| FY2024 | $627.2M | -$177.0M | -$0.48 | -$158.1M | -49.3% | -50.4% |
| FY2023 | $285.1M | -$518.3M | -$1.47 | -$413.4M | -185.2% | -243.6% |
| FY2022 | $117.0M | -$446.3M | -$1.40 | -$222.2M | — | -809.7% |
| FY2021 | $89.8M | -$386.2M | -$1.37 | -$242.4M | — | 394.0% |
| FY2020 | $75.7M | -$303.5M | -$1.28 | -$268.8M | — | -385.6% |
| FY2019 | $57.3M | -$133.0M | -$0.66 | -$121.7M | — | 232.8% |
| FY2018 | $49.1M | -$2.8M | -$0.01 | $286.7M | — | -26.7% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Legend Biotech Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Legend Biotech Corp has historically struggled to out-earn its cost of capital, averaging just -15.2% ROIC.
Legend Biotech Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Legend Biotech Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-26.90 per share.